Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trimethoprim-sulfamethoxazole versus levofloxacin for the treatment of Stenotrophomonas maltophilia infections: A multicentre cohort study.
Almangour TA, Alkherb Z, Alruwaite S, Alsahli R, Alali H, Almohaizeie A, Almuhisen S, Alowais SA, Saleh KB, Fetyani L, Alnashmi F, Alghofaily A, Abouobaid NI, Binkhamis KM, Tawfik EA, Alsowaida YS. Almangour TA, et al. Among authors: almuhisen s. J Glob Antimicrob Resist. 2024 Sep;38:42-48. doi: 10.1016/j.jgar.2024.05.016. Epub 2024 May 30. J Glob Antimicrob Resist. 2024. PMID: 38821443 Free article.
Monotherapy versus combination for the treatment of Stenotrophomonas maltophilia: a multicenter cohort study.
Almangour TA, Alali HA, Alkherb Z, Alowais SA, Bin Saleh K, Almuhisen S, Almohaizeie A, Alsahli R, Alruwaite S, Alnashmi F, Fetyani L, Abouobaid NI, Alghofaily A, Binkhamis KM, Alsowaida YS. Almangour TA, et al. Among authors: almuhisen s. Expert Rev Anti Infect Ther. 2024 Nov;22(11):997-1005. doi: 10.1080/14787210.2024.2353704. Epub 2024 May 13. Expert Rev Anti Infect Ther. 2024. PMID: 38738566
Novel β-lactam-β-lactamase inhibitors as monotherapy versus combination for the treatment of drug-resistant Pseudomonas aeruginosa infections: A multicenter cohort study.
Almangour TA, Ghonem L, Alassiri D, Aljurbua A, Al Musawa M, Alharbi A, Almuhisen S, Alghaith J, Damfu N, Aljefri D, Alfahad W, Alrasheed M, Khormi Y, Almohaizeie A. Almangour TA, et al. Among authors: almuhisen s. J Infect Chemother. 2024 Oct;30(10):1008-1014. doi: 10.1016/j.jiac.2024.03.015. Epub 2024 Mar 25. J Infect Chemother. 2024. PMID: 38537776
Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study.
Almangour TA, Ghonem L, Alassiri D, Aljurbua A, Al Musawa M, Alharbi A, Almohaizeie A, Almuhisen S, Alghaith J, Damfu N, Aljefri D, Alfahad W, Khormi Y, Alanazi MQ, Alsowaida YS. Almangour TA, et al. Among authors: almuhisen s. Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0040523. doi: 10.1128/aac.00405-23. Epub 2023 Jul 5. Antimicrob Agents Chemother. 2023. PMID: 37404159 Free PMC article.
Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study.
Almangour TA, Aljabri A, Al Musawa M, Almohaizeie A, Almuhisen S, Damfu N, Alfozan A, Alraddadi BM, Alattas M, Qutub M, Alhameed AF, Khuwaja M, Alghamdi A, Binkhamis KM, Alfahad W, AlShahrani FS. Almangour TA, et al. Among authors: almuhisen s. J Glob Antimicrob Resist. 2022 Mar;28:288-294. doi: 10.1016/j.jgar.2022.01.023. Epub 2022 Feb 1. J Glob Antimicrob Resist. 2022. PMID: 35121161 Free article.